Dovitinib (CHIR258, TKI258): structure, development and preclinical and clinical activity
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Dovitinib (CHIR258, TKI258): structure, development and preclinical and clinical activity
Authors
Keywords
-
Journal
Future Oncology
Volume 11, Issue 1, Pages 39-50
Publisher
Future Medicine Ltd
Online
2015-01-09
DOI
10.2217/fon.14.208
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A phase II study of dovitinib (TKI258), an FGFR- and VEGFR-inhibitor, in patients with advanced or metastatic renal cell cancer (mRCC).
- (2017) E. Angevin et al. JOURNAL OF CLINICAL ONCOLOGY
- The N550K/H Mutations in FGFR2 Confer Differential Resistance to PD173074, Dovitinib, and Ponatinib ATP-Competitive Inhibitors
- (2015) Sara A Byron et al. NEOPLASIA
- The ins and outs of fibroblast growth factor receptor signalling
- (2014) Stacey J. Coleman et al. CLINICAL SCIENCE
- Roles of Epithelial-Mesenchymal Transition in Cancer Drug Resistance
- (2014) Yulong Shang et al. CURRENT CANCER DRUG TARGETS
- Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial
- (2014) Robert J Motzer et al. LANCET ONCOLOGY
- Phase II study of dovitinib in patients with metastatic and/or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib
- (2013) Y-K Kang et al. BRITISH JOURNAL OF CANCER
- Ponatinib circumvents all types of imatinib resistance in chronic myelogenous leukemia cell lines
- (2013) Ophelie Cassuto et al. CELL CYCLE
- Phase I Study of Dovitinib (TKI258), an Oral FGFR, VEGFR, and PDGFR Inhibitor, in Advanced or Metastatic Renal Cell Carcinoma
- (2013) E. Angevin et al. CLINICAL CANCER RESEARCH
- Targeting FGFR with Dovitinib (TKI258): Preclinical and Clinical Data in Breast Cancer
- (2013) F. Andre et al. CLINICAL CANCER RESEARCH
- Phase III Randomized, Placebo-Controlled Study of Cetuximab Plus Brivanib Alaninate Versus Cetuximab Plus Placebo in Patients With Metastatic, Chemotherapy-Refractory, Wild-TypeK-RASColorectal Carcinoma: The NCIC Clinical Trials Group and AGITG CO.20 Trial
- (2013) Lillian L. Siu et al. JOURNAL OF CLINICAL ONCOLOGY
- Brivanib Versus Sorafenib As First-Line Therapy in Patients With Unresectable, Advanced Hepatocellular Carcinoma: Results From the Randomized Phase III BRISK-FL Study
- (2013) Philip J. Johnson et al. JOURNAL OF CLINICAL ONCOLOGY
- Brivanib in Patients With Advanced Hepatocellular Carcinoma Who Were Intolerant to Sorafenib or for Whom Sorafenib Failed: Results From the Randomized Phase III BRISK-PS Study
- (2013) Josep M. Llovet et al. JOURNAL OF CLINICAL ONCOLOGY
- FGF Receptors: Cancer Biology and Therapeutics
- (2013) Masaru Katoh et al. MEDICINAL RESEARCH REVIEWS
- A Proangiogenic Signature Is Revealed in FGF-Mediated Bevacizumab-Resistant Head and Neck Squamous Cell Carcinoma
- (2013) R. Gyanchandani et al. MOLECULAR CANCER RESEARCH
- Activity of the Fibroblast Growth Factor Receptor Inhibitors Dovitinib (TKI258) and NVP-BGJ398 in Human Endometrial Cancer Cells
- (2013) G. E. Konecny et al. MOLECULAR CANCER THERAPEUTICS
- A Phase 2 Trial of Ponatinib in Philadelphia Chromosome–Positive Leukemias
- (2013) J.E. Cortes et al. NEW ENGLAND JOURNAL OF MEDICINE
- Molecular Mechanisms of Fibroblast Growth Factor Signaling in Physiology and Pathology
- (2013) A. A. Belov et al. Cold Spring Harbor Perspectives in Biology
- Dovitinib sensitizes hepatocellular carcinoma cells to TRAIL and tigatuzumab, a novel anti-DR5 antibody, through SHP-1-dependent inhibition of STAT3
- (2012) Kuen-Feng Chen et al. BIOCHEMICAL PHARMACOLOGY
- The anticancer multi-kinase inhibitor dovitinib also targets topoisomerase I and topoisomerase II
- (2012) Brian B. Hasinoff et al. BIOCHEMICAL PHARMACOLOGY
- Disposition and metabolism of 14C-dovitinib (TKI258), an inhibitor of FGFR and VEGFR, after oral administration in patients with advanced solid tumors
- (2012) Anne-Charlotte Dubbelman et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Brivanib: a review of development
- (2012) Tina Chou et al. Future Oncology
- Population Pharmacokinetic/Pharmacodynamic Modeling to Assist Dosing Schedule Selection for Dovitinib
- (2012) Xiaofeng Wang et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Dovitinib preferentially targets endothelial cells rather than cancer cells for the inhibition of hepatocellular carcinoma growth and metastasis
- (2012) Zhi-Yuan Chen et al. Journal of Translational Medicine
- Changes in Circulating Pro-Angiogenic Cytokines, other than VEGF, before Progression to Sunitinib Therapy in Advanced Renal Cell Carcinoma Patients
- (2012) Camillo Porta et al. ONCOLOGY
- FGFR2 Point Mutations in 466 Endometrioid Endometrial Tumors: Relationship with MSI, KRAS, PIK3CA, CTNNB1 Mutations and Clinicopathological Features
- (2012) Sara A. Byron et al. PLoS One
- A Validated Tumorgraft Model Reveals Activity of Dovitinib Against Renal Cell Carcinoma
- (2012) S. Sivanand et al. Science Translational Medicine
- Fibroblast growth factors and their receptors in cancer
- (2011) Jørgen Wesche et al. BIOCHEMICAL JOURNAL
- Phase I/II and Pharmacodynamic Study of Dovitinib (TKI258), an Inhibitor of Fibroblast Growth Factor Receptors and VEGF Receptors, in Patients with Advanced Melanoma
- (2011) K. B. Kim et al. CLINICAL CANCER RESEARCH
- Endothelial mesenchymal transformation mediated by IL-1β-induced FGF-2 in corneal endothelial cells
- (2011) Jeong Goo Lee et al. EXPERIMENTAL EYE RESEARCH
- Brivanib alaninate for cancer
- (2011) Ivan Diaz-Padilla et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Heparanase and Syndecan-1 Interplay Orchestrates Fibroblast Growth Factor-2-induced Epithelial-Mesenchymal Transition in Renal Tubular Cells
- (2011) Valentina Masola et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Dovitinib demonstrates antitumor and antimetastatic activities in xenograft models of hepatocellular carcinoma
- (2011) Hung Huynh et al. JOURNAL OF HEPATOLOGY
- Orthotopic xenografts of RCC retain histological, immunophenotypic and genetic features of tumours in patients
- (2011) Chiara Grisanzio et al. JOURNAL OF PATHOLOGY
- Dovitinib Induces Apoptosis and Overcomes Sorafenib Resistance in Hepatocellular Carcinoma through SHP-1-Mediated Inhibition of STAT3
- (2011) W.-T. Tai et al. MOLECULAR CANCER THERAPEUTICS
- Hypoxia-Inducible Factors and the Response to Hypoxic Stress
- (2010) Amar J. Majmundar et al. MOLECULAR CELL
- Resistance to targeted therapy in renal-cell carcinoma
- (2009) Brian I Rini et al. LANCET ONCOLOGY
- Brivanib Alaninate, a Dual Inhibitor of Vascular Endothelial Growth Factor Receptor and Fibroblast Growth Factor Receptor Tyrosine Kinases, Induces Growth Inhibition in Mouse Models of Human Hepatocellular Carcinoma
- (2008) H. Huynh et al. CLINICAL CANCER RESEARCH
- A Phase I Pharmacokinetic and Pharmacodynamic Study of TKI258, an Oral, Multitargeted Receptor Tyrosine Kinase Inhibitor in Patients with Advanced Solid Tumors
- (2008) D. Sarker et al. CLINICAL CANCER RESEARCH
- Discovery of Brivanib Alaninate ((S)-((R)-1-(4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan-2-yl)2-aminopropanoate), A Novel Prodrug of Dual Vascular Endothelial Growth Factor Receptor-2 and Fibroblast Growth Factor Receptor-1 Kinase Inhibitor (BMS-540215)
- (2008) Zhen-wei Cai et al. JOURNAL OF MEDICINAL CHEMISTRY
- Drug-sensitive FGFR2 mutations in endometrial carcinoma
- (2008) A. Dutt et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started